ELVN
Enliven Therapeutics Inc.NASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$2.63B
P/E Ratio
—
EPS
$-1.83
Beta
0.49
52W High
$46.31
52W Low
$14.79
50-Day MA
$32.22
200-Day MA
$23.50
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Enliven Therapeutics Inc.
Enliven Therapeutics Inc. (Ticker: ELVN) is a pioneering biotechnology firm dedicated to revolutionizing cancer therapy and tackling other critical illnesses through its proprietary therapeutic platforms. The company boasts a robust pipeline of innovative drug candidates developed via advanced biopharmaceutical technologies aimed at improving patient outcomes and enhancing quality of life. With a strong emphasis on scientific innovation and a commitment to addressing significant unmet medical needs in oncology, Enliven is well-positioned to drive shareholder value and make meaningful contributions to the healthcare ecosystem.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-119.39M |
| Operating Margin | 0.00% |
| Return on Equity | -27.00% |
| Return on Assets | -18.60% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $7.73 |
| Price-to-Book | 5.72 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | -6.28 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $59.80M |
| Float | $34.14M |
| % Insiders | 8.21% |
| % Institutions | 106.66% |
Historical Volatility
HV 10-Day
69.20%
HV 20-Day
88.13%
HV 30-Day
78.98%
HV 60-Day
65.65%
HV Rank
—
Volatility is currently contracting
Analyst Ratings
Consensus ($51.00 target)
8
BuyData last updated: 4/16/2026